NurExone Biologic Inc.

Recent News

• United States Patent Office Allows Patent to Exosome Biomedical Company NurExone

  Haifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. Patent Application NO. 17/042,441 ("the Patent"). The Patent covers and protects NurExone Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of...

  2023-01-12 8:51 AM EST
• NurExone Issues Annual Shareholder Letter

  Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to provide the following shareholder letter from NurExone CEO Dr. Lior Shaltiel.Dear Shareholders, We started our journey to provide much-needed therapy for people who have suffered spinal cord injuries and have accomplished very significant achievements in 2022. As we progress with developing...

  2022-12-15 8:30 AM EST
• NurExone Announces Completion of Securites for Debt Settlement

  Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it completed its securities for debt settlement on December 6, 2022, previously announced by the Company on November 24, 2022. The Company agreed to settle debts in the aggregate amount of CAD$46,523.69 with the issuance of 122,430 common shares...

  2022-12-07 6:17 PM EST
• Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

  NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error.Calgary, Alberta--(Newsfile Corp. - December 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, reported today results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology...

  2022-12-01 2:30 PM EST
• NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

  Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, reported today results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology has the potential to serve as an efficient process for loading of therapeutic molecular cargo into exosomes. In exosome-based therapies, loaded exosomes are...

  2022-11-30 8:30 AM EST
• NurExone Announces Securities for Debt Settlement

  Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at a deemed price of CAD$0.38 per share.These debts were incurred prior to the recent Reverse Takeover Transaction following which...

  2022-11-24 7:17 PM EST
• NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter ended September 30, 2022."Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request," said Dr. Lior...

  2022-11-24 8:00 AM EST
• NurExone Announces Completion of Securities for Debt Settlements

  Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by the Company on September 1, 2022 and September 19, 2022. The Company agreed to settle debts in the aggregate amount of CAD$136,155.83 with the issuance of 170,195 common...

  2022-11-08 5:01 PM EST
• NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration

  The U.S. Food and Drug Administration (FDA) informed NurExone that it is at the appropriate stage of its product development for a pre-Investigational New Drug (pre-IND) meetingA pre-IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into the U.S. market.Calgary, Alberta--(Newsfile Corp. - November 2, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased...

  2022-11-02 8:00 AM EDT
• NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production

  Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced today results of an internal productivity and quality pilot that was completed by the Company and the Technion - Israel Institute of Technology in Q2 2022 pursuant to the previously announced Sponsor Research Agreement, showing that its innovative and proprietary production process has the potential...

  2022-10-26 9:00 AM EDT